Home

Welcome to imetelstat.eu

This website collects academic, clinical and commercial information about the new drug imetelstat : the first telomerase inhibitor in clinical stage development. Imetelstat inhibits the activity of telomerase, which is an enzyme present in most types of cancer that enables tumor cells to replicate indefinitely.

The purpose of imetelstat.eu is to provide easy access to existing information about imetelstat , its basic workings, clinical potential and results from preclinical and clinical studies. Imetelstat.eu only publishes content that is publicly available and from known sources.

This website is a private initiative. It operates independently and is not funded by external parties.

Imetelstat.eu aims to be helpful for everyone interested in imetelstat , whether they are patients, relatives, scientists, investors or simply curious. People are encouraged to contact the administrator through the contact form of this site to provide suggestions for new information about imetelstat that should be uploaded to this website.

Go to Mayo Study / NCT01731951

Go to IMBark / NCT02426086

Go to IMerge / NCT02598661

Pre-clinical

There exists a history of preclinical research on telomerase and imetelstat, ignited after the discovery of telomerase by Carol Greider and Elisabeth Blackburn in 1984. This section provides you with an archive of past and present scientific research, including links to papers, reports, presentations and other information.

Clinical

Imetelstat has been evaluated and tested in a variety of clinical trials and for various indications. Here you can find an overview of past and current clinical trial, as well as relevant reports, presentations and abstracts from those trials.

Commercial

This section provides information on the commercial development of imetelstat. This may include relevant messages from and about organizations that are in the business of developing, manufacturing and commercialising imetelstat.

News

2018:

08-02-2018 - Janssen Biotech applies for global patent for COMBINATION TREATMENT FOR HEMATOLOGICAL CANCERS , including imetelstat

2017:

Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes (20 November 2017)

Geron Announces Presentations at American Society of Hematology Annual Meeting Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes to be Presented (1 November 2017)

4 abstracts on imetelstat at ASH2017 (9-12 December 2017)

Geron Announces Updates to Imetelstat Clinical Development (31 july 2017)

Geron PR confirms: IMbark and IMerge Continue after Second Internal Data Reviews (10 April 2017)

JnJ Poster AACR2017 Venetoclax/imetelstat combo for AML now available

New article: Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis (Leukemia, 8 MArch 2017)

Geron files new patent: Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms (23 February 2017)

JnJ to present pre-clinical results on imetelstat-venetoclax combination therapy for AML at AACR 2017

Telomere Length Linked to Genomic Alterations in 31 Cancers (Genomeweb, 30 January 2017)

Systematic analysis of telomere length and somatic alterations in 31 cancer types (Nature Genetics, 30 January 2017)

Telomerase antagonist imetelstat increases radiation sensitivity in esophageal squamous cell carcinoma (Oncotarget, 13 January 2017)

Geron January 2017 corporate presentation

2016:

Geron Files new patent: Synthesis of protected 3'-amino nucleoside monomers (filed May 16, 2016)

Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting (Menlo Park, 6 December 2016)

Researchers uncover key mechanisms of cancer, aging and inflammation (Medical Press, 7 November 2016)

New patent application by Geron: Methods of polynucleotide preparation using multivalent cation salt compositions (application filed 27 October 2016)

Imetelstat at ASH2016: abstracts accepted on AML, CML and ET (released 3 November 2016)

Article: Telomerase as a Cancer Target. Development of New Molecules (M. Gomez et al, September 2016)

New patent application by Geron: Method for eliciting an immune response to human telomerase reverse transcriptase (application filed 15 September 2016)

S.Gryaznov (JnJ/Olios) to present about imetelstat ath the 12th Annual Meeting of the Oligonucleotide Therapeutics Society (28 September 2016, 15.50 - 16.10 hrs)

Geron provides update on IMbark and IMerge (12 September 2016)

Dr. Ayalev Tefferi to speak at 2nd Annual SF Bay Area MPN Conference for Patients on 17 September 2016

Dr. Alessandro Vannucchi speaks about imetelstat at the European MPN Focus Meeting in Zagreb (Youtube, published 20 May 2016)

Geron Announces Issuance of U.S. Patents Related to Imetelstat (13 July 2016)

Geron announces new patent protection involving the use of any telomerase inhibitor to treat MF, MDS, or CMML (US9375485, 28 June 2016)

Abstract + Poster Presentation by A. Tefferi at ASCO 2016 now available (presentation was on Monday June 6, 8:00 AM to 11:30 AM)

Geron 2016 Annual Meeting of Stockholders (Tuesday, May 17, 2016 7:00 p.m. ET)

Morgan Stanley raised its position in shares of Geron Co. by 194.2% (Ticker Report, 21 April 2016)

Ayalew Tefferi to present Poster Board session at ASCO2016

Two poster presentations about Imetelstat from AACR 2016 now available (posters 2731 and 2732)

Geron to present at the the Needham Healthcare Conference on April 12, 2016 (Geron, 5 April 2016)

Geron Corp files 10-K forms / Annual Report (10 March, 2016)

Two presentations on imetelstat on AACR2016 . There will be 3 additional presentation about telomerase. All 5 presentations are in the session 'Molecular and Cellular Biology / Genetics' on April 19, 2016, 08.00 - 12.00 AM .

February 23, 2016 - Slides of Geron's presentation at the Feb 23 presentation at the RBC Captial Markets 2016 Global Healthcare Conference are for download at the Geron Homepage: www.geron.com

Geron Announces Initiation of Janssen Phase 2/3 Clinical Trial of Imetelstat in Myelodysplastic Syndromes and ODD for MDS in the US (Geron, 14 January 2016)

Geron Corporate Presentation 2016 available (filed 11 January 2016 as exhibit of the SEC K-8 form)

2015:

ASH 2015 Abstracts avaialble (57th ASH Annual Meeting and Exhibition, Orlande - FL, 5-8 December 2015)

Geron announces Presentations at 57th American Societyof Hematology Annual Meeting (Global Newswire, Nov 05, 2015)

A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) (www.clinicaltrials.gov, updated November 2015)

Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis, MDS and Other Myeloid Malignancies (NCT01731951), now open for recrutement (www.clinicaltrials.gov, updated 23 September 2015)

Geron Announces Initiation of Janssen Phase 2 Clinical Trial of Imetelstat in Myelofibrosis (Geron, 16 September 2015)

A Pilot Study of the Telomerase Inhibitor Imetelstat for Myelofibrosis (The New England Journal of Medicine, 2015)

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia (The New England Journal of Medicine, 2015)

Dual Publications in the New England Journal of Medicine Highlight Transformative Potential of Imetelstat in Hematologic Myeloid Malignancie s (Geron, 3 September 2015)

ASH 2015: Scientific Meeting on Telomeres and Bone Marrow Failure

Geron Corp (GERN) Announces Receipt of FDA Orphan Drug Designation for Imetelstat as Myelofibrosis Treatment (StreetInsider.com, 15 June, 2015)

Videos

Elisabeth Blackburn, nobel prize winner for the discovery of telomeres and telomerase, explains telomerase mechanisms, its impact on medical science and the potential treatment of certain diseases.

1) Discovery of Telomeric DNA and Telomerase

2) The Roles of Telomeres and Telomerase

3) Telomeres and Telomerase in Human Stem Cells and in Cancer

4) Stress, Telomeres and Telomerase in Humans

5) Elisabeth Blackburn - Facts (nobelprize.org)

-------------------------------------------------------------------------------------

CSHL 2015 Symposium Interview Series with Titia de Lange (Youtube)

Dr. Titia de Lange from the Rockefeller University Institute Australia speaks about telomeres and telomerase, and its promise as a target to fight cancer. The interview is taken at the Cold Spring Harbor Laboratory Symposium '21st Century Genetics' on 30 May 2015.

-------------------------------------------------------------------------------------

Articles

Telomeres, Telomerase and Cancer

by Carol W. Greider and Elizabeth H. Blackburn (Scientific Amarican, 2009)

During the past 15 years, investigation of this unexpected flux has produced a number of surprising discoveries. In particular, it has led to identification of an extraordinary enzyme named telomerase that acts on telomeres and is thought to be required for the maintenance of many human cancers. This last finding has sparked much speculation that drugs able to inhibit the enzyme might combat a wide array of malignancies.